Cooperative Agreement U01FD006676

Khloris Biosciences, Inc. received a $3.46 million Project Grant from the National Institutes of Health National Heart, Lung and Blood Institute to develop and validate a collection of induced pluripotent stem cell-derived cardiomyocyte cell lines. Under the Cardiovascular Diseases Research program (CFDA 93.837), Khloris will establish 50 cell lines from healthy individuals and patients with common hereditary cardiac disorders such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and long...

This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...

The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $507,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop an automated system that integrates micro-electromechanical sensors, automation, and machine vision to simultaneously measure the electrophysiological properties and contractile forces of single human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). This...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,289,113 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Oregon Health & Science University (OHSU) to study the use of imaging and genetic testing to improve risk prediction for sudden cardiac death in children and adolescents with hypertrophic cardiomyopathy (HCM). The 4-year project, titled "IPRISM (IMAGING-ENHANCED PREDICTION OF RISK FOR SUDDEN CARDIAC DEATH IN HCM) - PROJECT...

This $590,283 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop feedback-controlled closed-loop manufacturing processes for differentiating human pluripotent stem cells into cardiomyocytes. The key objectives are to: 1) Identify failure modes in 2D cardiomyocyte differentiation through integrated single-cell transcriptomics and epigenomics, and 2) Develop control strategies to enhance the reproducibility of human...

This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...

This Cooperative Agreement award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $1,498,464 to Kaiser Foundation Hospitals to develop and validate AI-enabled echocardiographic biomarkers and integrate real-world electronic health record data to improve early detection and risk stratification of cancer therapy-related cardiac dysfunction (CTRCD). The project aims to transform cardio-oncology care by leveraging a diverse cohort of over 34,000 patients treated...

The National Science Foundation awarded Cardiophi LLC $532,000 under the Technology, Innovation, and Partnerships program to develop an artificial intelligence solution for the automated interpretation of electrocardiograms. The project aims to refine existing deep learning-based algorithms for detecting irregular heartbeats, develop methods for predicting the onset of cardiac arrhythmias, and create interpretable and explainable tools to provide insights from ECG signals to clinicians....

The federal Project Grant award of $297,720 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to demonstrate the predictive capabilities of the MUSICO (Muscle Simulation Code) in silico platform for evaluating the effects of disease and drug effectiveness in hypertrophic (HCM) and dilated (DCM) cardiomyopathies. The project will conduct rodent studies, human-induced pluripotent stem cell-derived cardiomyocyte experiments, and porcine heart...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...